Introduction
============

Venous thromboembolism (VTE), consisting mainly of deep vein thrombosis (DVT) and pulmonary embolism, is a typical multifactorial disease and genetic and environmental factors both contribute to the risk of developing this disease \[[@R1]\]. Genetic risk factors for VTE affect natural anticoagulant mechanisms and result in a hypercoagulable state, which include rare gene variants of anticoagulant factors as well as common gene variants, such as factor V Leiden and prothrombin G20210A. The latter two gene variants are prevalent among Caucasian populations, but have yet to be identified among non-Caucasians \[[@R2]\].

A high prevalence of dysfunctions in the natural anticoagulant factors, protein S and protein C, have been reported among Japanese and Chinese VTE patients \[[@R3]\]. By systematical gene analyses, we identified a protein S gene (*PROS1*) variant with a plasma phenotype of qualitative (type II) deficiency, protein S Tokushima (p.Lys196Glu, rs121918474), as a genetic risk factor for DVT with an allele frequency of 0.8% in the Japanese population and a 3.7-fold higher risk of DVT among heterozygotes \[[@R4]\]. Similar findings were independently reported in two other case\--control studies \[[@R5],[@R6]\]. Two protein C gene (*PROC*) variants, p.Arg189Trp (rs146922325) \[[@R7],[@R8]\] and p.Lys193del (rs199469469) \[[@R9]\], have been identified as genetic risk factors for VTE in the Chinese population with allele frequencies of 0.4 and 1.2%, and five-to-seven-fold and three-fold higher risks of VTE among heterozygotes, respectively. The plasma phenotype of these protein C gene variants is also a type II deficiency.

Protein S and protein C are both vitamin K-dependent glycoproteins and function as the main components of the protein C anticoagulant system \[[@R10]\]. Thrombin complexed with thrombomodulin rapidly activates protein C, and activated protein C (APC) inhibits the coagulation pathway by the proteolysis of factors Va and VIIIa. In plasma, approximately 40% of protein S circulates in its free form (free protein S), with the remaining 60% being noncovalently bound to the β chain of C4b-binding protein (C4BP), an important regulator of the complement system. Free protein S serves as a cofactor to APC, whereas the protein S-C4BP complex loses its cofactor activity. The dissociation of the protein S-C4BP complex is extremely slow in the presence of a physiological concentration of Ca^2+^, whereas its affinity is significantly decreased in the absence of Ca^2+^\[[@R11]\].

The laboratory screening of a type II deficiency in anticoagulant factors is currently achieved by measuring plasma activities and compared them to antigen levels \[[@R12],[@R13]\]. Protein C activity is measured by either a clot-based assay, mostly based on activated partial thromboplastin time (APTT), or a chromogenic-based assay; however, the latter is not able to detect abnormalities in cofactor binding, surface binding, and other substrate-binding regions, such as the protein C p.Lys193del variant \[[@R9]\]. The measurement of protein S levels is more complicated because of its cofactor function and partitioning into two forms in plasma. Protein S activity is commonly measured by a clot-based assay, mostly based on APTT or prothrombin time (PT), and is compared with the free protein S level for diagnosing type II protein S deficiency. However, the clot-based assays are considered not to be specific enough to diagnose protein S deficiency because of many preanalytical variables \[[@R12]--[@R15]\]. Thus, we established a total protein S assay system in which the undesired effects of the dissociation of the protein S-C4BP complex are avoided and protein S activity is measured by a chromogenic-based assay, thereby enabling the accurate diagnosis of a type II protein S deficiency, such as protein S Tokushima \[[@R16]\].

Plasma protein S levels are lower in women than in men, as are levels in premenopausal women than in postmenopausal women \[[@R17],[@R18]\], and they significantly decrease during pregnancy and oral contraceptive use \[[@R19],[@R20]\]. The aim of the present study was to examine the prevalence of protein S Tokushima and two *PROC* variants, p.Arg189Trp and p.Lys193del, in young Japanese women, and to perform plasma phenotype analyses in order to diagnosing the carriers of these gene variants.

Materials and methods
=====================

Participants and blood sampling
-------------------------------

The present study was approved by the Ethics Committee of Nakamura Gakuen University. In April 2013 and 2014, female Japanese students (*n* = 231, 20.0 ± 0.6 years) of the Department of Nutritional Sciences of Nakamura Gakuen University who participated in health check-ups were recruited and all target participants provided written informed consent. Following an overnight fast, venous blood was collected early in the morning into tubes containing a one-tenth volume of 0.105 mol/l sodium citrate and were kept on ice for no longer than 3 h, centrifuged at 1500 × *g* at 4 °C for 10 min, and platelet-poor plasma samples were stored in aliquots and frozen at −70 °C for later analyses. Genomic DNA was purified from the buffy coat of citrated blood samples using NucleoSpin Blood QuickPure (TaKaRa Bio Inc., Shiga, Japan) and stored at −20 °C.

Genotyping of *PROS1* and *PROC* variants
-----------------------------------------

The genotypes of protein S Tokushima (p.Lys196Glu, c.586A\>G) and protein C p.Arg189Trp (c.565C\>T) were assessed by a combination of real-time PCR and Cycling probe method using Cycleave PCR Reaction Mix (Takara Bio Inc.). The primers and probes used for protein S p.Lys196Glu genotyping were 5′-CTCCTGAAAAGTTCTCTGCA/5′-AAATTTCTCTAACTGGGATT and 5′-Eclipse-GCTTTCAAATaAG-FAM (the A allele)/5′-Eclipse-AATCTTTCTcATT-ROX (the G allele), respectively, and those for protein C p.Arg189Trp genotyping were 5′-AAGACAGGAGGGCAGTCTCG/5′-AGCCGCGGATCTACTTGGTC and 5′-Eclipse-GAAGcGGAT-FAM (the C allele)/5′-Eclipse-GGAAGtGGAT-ROX (the T allele), respectively. The genotype of protein C p.Lys193del (c.574_576delAAG) was assessed by the TaqMan method using Premix Ex Taq (Probe qPCR) (Takara Bio Inc.) and the primers and probes used were 5′-AAGACAGGAGGGCAGTCTCG/5′-AGCCGCGGATCTACTTGGTC and 5′-Eclipse-GATGGAGAAGAAGCGCAGTC-ROX (the AAG allele)/5′-Eclipse-GATGGAGAAGCGCAGTCACC -- FAM (the delAAG allele), respectively. PCR reactions were performed using a Thermal Cycler Dice Real Time System II (Takara Bio Inc.).

Analyses of plasma protein S and protein C phenotypes
-----------------------------------------------------

Frozen plasma samples that had never thawed before analyses were thawed in a water bath at 37 °C within 5 min. In the total protein S assay system, total protein S activity and antigen levels were measured by the chromogenic method and latex agglutination method, respectively, using a Hitachi 7180 automated analyzer (Hitachi High-Technologies, Tokyo, Japan), as described in our pervious study \[[@R16]\] with a slight modification to improve applicability. Briefly, in total protein S activity measurements, the protein S-C4BP complex in plasma was initially dissociated by diluting samples 126 times with dilution buffer containing APC and FXa, and 3 μl of diluted plasma was then mixed with 150 μl of the reagent containing FVa, liposome, and CaCl~2~. After incubating for 5 min, 50 μl of the reagent containing prothrombin and S-2238, a chromogenic substrate for thrombin, was added and the absorbance change was evaluated at the main wavelength of 405 nm with an auxiliary wavelength of 450 nm for 5 min. In total protein S antigen measurements, free protein S in plasma was initially combined with C4BP by incubating 3 μl of samples with 100 μl of the reagent containing an excess amount of purified human C4BP. After incubating for 5 min, 100 μl of the reagent containing monoclonal anti-protein S antibody (9H6)-bound latex particles was added and the absorbance change was assessed at 700 nm for 5 min. Total protein S activity and antigen levels were expressed as IU/dl using the WHO second International Standard for protein S (03/228, NIBSC, Hertfordshire, UK). The total protein S activity/total protein S antigen ratio, protein S-specific activity, was then calculated. The intraassay and interassay coefficients of variations (*n* = 5) of the total protein S activity assay, determined using three plasma samples of different protein S levels, were 0.4--1.9 and 1.5--2.8%, respectively, whereas those of the total protein S antigen assay were 0.7--1.8 and 1.2--1.6%, respectively. The reference intervals \[mean ± 2 × standard deviation (SD)\] were assessed by sex using the data of healthy Japanese individuals (*n* = 194, women 40.7%): those of total protein S activity and total protein S antigen levels for women, 74--134 and 74--127 IU/dl, respectively; those for men, 82--138 and 80--131 IU/dl, respectively. The total protein S activity/total protein S antigen ratio showed no sex difference, and its reference interval was 0.86--1.18 for both sexes.

The clot-based activity assays of protein S and protein C and the latex agglutination-based antigen assays of free protein S and protein C were performed in the laboratory of SRL, Inc. (Tokyo, Japan) using commercial kits. PT-based protein S activity was measured using HemosIL protein S clot (Instrumentation Laboratory Co., Bedford, USA), APTT-based protein C activity using HemosIL professional clot (Instrumentation Laboratory Co.), free protein S antigen levels using STA-Liatest Free protein S (Diagnostica Stago, Inc. Parsippany, New Jersey, USA), and protein C antigen levels using LPIA-ACE protein C (LSI Medience Co., Tokyo, Japan). Data were expressed as U/dl using normal pooled plasma as a standard: protein S activity using HemosILCalibration Plasma (Instrumentation Laboratory Co.) and protein C activity, free protein S antigen, and protein C antigen levels using local pooled plasma obtained from approximately 100 healthy Japanese individuals including both sexes. The protein S activity/free protein S antigen ratio and protein C activity/protein C antigen ratio were then calculated. The reference interval of protein S activity was 56--126 U/dl for women and 67--164 U/dl for men, and those of free protein S antigen, protein C activity, and protein C antigen were 60--150, 64--146, and 70--150 U/dl, respectively, for both sexes.

Statistical analysis
--------------------

Data were expressed as the mean ± SD and compared using unpaired Student\'s *t*-tests. Univariate linear regression analyses were performed and Pearson\'s correlation coefficients were calculated. The diagnostic accuracy of the parameters of plasma analyses was assessed from the receiver-operating characteristic (ROC) curves, and the areas under the curve (AUC) with their 95% confidence intervals (CIs) were assessed using a logistic regression analysis. The corresponding sensitivity and specificity values were calculated using the value closest to the lower limit of the reference interval of each parameter as a cut-off value. Statistical analyses were performed using PASW Statistics ver. 23 (SPSS Inc., Chicago, Illinois, USA), and a *P* value of less than 0.05 indicated significance.

Results
=======

Genotyping of *PROS1* and *PROC* variants
-----------------------------------------

Five (2.2%) out of 231 participants were identified as heterozygous carriers for protein S Tokushima (p.Lys196Glu) with an allele frequency of 1.08%. Four (1.7%) were heterozygous carriers for protein C p.Lys193del with an allele frequency of 0.86%; however, any carrier of protein C p.Arg189Trp was not found. Neither a homozygote nor a double heterozygote of protein S Tokushima and protein C p.Lys193del was identified. Therefore, 1 out of every 25 target individulas were found to have a genetic risk factor for VTE.

Plasma phenotypic analyses
--------------------------

We then compared plasma protein S and protein C levels according to the genotypes of these variants. Before analyses, six individuals were excluded: four for taking oral contraceptives and two with amenorrhea. The remaining 225 individuals, including 9 heterozygous carriers for either protein S Tokushima (p.Lys196Glu) or protein C p.Lys193del variant, did not have a disease or take medication that influences plasma protein S and protein C levels. As shown in Table [1](#T1){ref-type="table"}, the total protein S activities of heterozygous individuals for protein S p.Lys196Glu variant (Lys/Glu, *n* = 5) were significantly lower than those of wild-type individuals (Lys/Lys, *n* = 220), whereas no significant difference was observed in total protein S antigen levels between two groups. As a result, the total protein S activity/total protein S antigen ratios of the heterozygotes were significantly lower than those of wild-type individuals. As expected, no significant difference was observed in protein C activity or protein C antigen levels between two groups. Regarding protein C p.Lys193del variants, the clot-based protein C activities of heterozygous individuals (Lys/del, *n* = 4), all being within the reference interval, were not significantly different from those of wild-type individuals (Lys/Lys, *n* = 221). However, the protein C antigen levels of heterozygotes were significantly higher than those of wild-type individuals, resulting in markedly lower clot-based protein C activity/protein C antigen ratios for heterozygotes than for wild-type individuals. As expected, no significant difference was noted in protein S levels between two groups. These results suggest the high sensitivity of the activity/antigen ratio (specific activity) for diagnosing a type II deficiency with moderately decreased or normal activity, such as protein S Tokushima (p.Lys196Glu) and protein C p.Lys193del variants and that the heterozygous carriers of protein C p.Lys193del variant cannot be identified by the clot-based protein C activity assay.

###### 

Protein S and protein C activities and antigen levels in wild-type and heterozygous individuals for the *PROS1 and PROC* variants

                                                           Protein S p.Lys196Glu   Protein C p.Lys193del                                         
  -------------------------------------------------------- ----------------------- ----------------------- --------- ------------- ------------- ---------
  Total protein S activity (IU/dl)                         97 ± 14                 67 ± 6                  \<0.001   96 ± 14       99 ± 13       0.734
  Total protein S antigen (IU/dl)                          97 ± 11                 99 ± 10                 0.706     97 ± 11       100 ± 11      0.579
  Total protein S activity/total protein S antigen ratio   1.00 ± 0.06             0.69 ± 0.03             \<0.001   0.99 ± 0.08   1.01 ± 0.05   0.626
  Clot-based protein C activity (U/dl)                     111 ± 23                123 ± 20                0.251     112 ± 23      90 ± 17       0.062
  Protein C antigen (U/dl)                                 102 ± 17                107 ± 9                 0.535     102 ± 16      121 ± 23      0.021
  Clot-based protein C activity/protein C antigen ratio    1.09 ± 0.17             1.15 ± 0.12             0.468     1.10 ± 0.17   0.75 ± 0.06   \<0.001

Data are expressed as means ± SD and differences between two groups were compared using an unpaired Student\'s *t*-test.

Diagnostic accuracy of plasma phenotype analyses for the protein S Tokushima variant
------------------------------------------------------------------------------------

Kimura *et al.*\[[@R21]\] previously reported that the clot (APTT)-based protein S activity assay was not sufficiently sensitive for identifying heterozygous carriers of protein S Tokushima (p.Lys196Glu) variant. In order to validate the diagnostic accuracy of protein S activity assays for the protein S Tokushima variant, we further measured PT-based protein S activity and free protein S antigen levels in the plasma samples of wild-type (Lys/Lys, *n* = 130) and heterozygous (Lys/Glu, *n* = 9) individuals for protein S Tokushima; the latter group included an additional four heterozygous female students, with none taking oral contraceptives, identified in 2018.

Figure [1](#F1){ref-type="fig"} shows the distributions of the parameters of plasma protein S phenotypic analyses. The PT-based protein S activities of wild-type individuals were significantly higher than those of heterozygous individuals (87 ± 14 vs. 64 ± 9 U/dl, *P* \< 0.001); however, were distributed over a wide range (40--136 U/dl) and overlapped completely with the range of heterozygous individuals (51--81 U/dl) (Fig. [1](#F1){ref-type="fig"}d). Three wild-type individuals had significantly decreased PT-based protein S activities of 40, 46, and 52 U/dl. The PT-based protein S activity/free protein S antigen ratios of wild-type individuals were significantly higher than those of heterozygous individuals (0.93 ± 0.12 vs. 0.66 ± 0.07, *P* \< 0.001); however, were widely distributed (0.40--1.32) and overlapped completely with those of the heterozygotes (0.58--0.78) (Fig. [1](#F1){ref-type="fig"}f). In contrast, the total protein S activities of wild-type individuals were distributed within a narrower range (67--136 IU/dl) than that of PT-based protein S activities, but partially overlapped with the levels of heterozygous individuals (64--89 IU/dl) (Fig. [1](#F1){ref-type="fig"}a). The distribution of the total protein S activity/total protein S antigen ratios of wild-type individuals (0.78--1.17) did not overlap with that of heterozygous individuals (0.65--0.77) (Fig. [1](#F1){ref-type="fig"}c). As expected, the distributions of total protein S antigen and free protein S antigen levels completely overlapped between the two groups (Fig. [1](#F1){ref-type="fig"}b and e). The total protein S activities and total protein S antigen levels of all target individulas (*n* = 139) correlated well with PT-based protein S activities (*r* = 0.626, *P* \< 0.001) and free protein S antigen levels (*r* = 0.681, *P* \< 0.001), respectively.

![Distributions of levels of total protein S activity (a), total protein S antigen (b), total protein S activity/total protein S antigen ratio (c), PT-based protein S activity (d), free protein S antigen (e), and PT-based protein S activity/free protein S antigen ratio (f) in wild-type (Lys/Lys, *n* = 130) and heterozygous individuals (Lys/Glu, *n* = 9) for the protein S Tokushima (p.Lys196Glu) variant. Total protein S activity and total protein S antigen levels were measured using the total protein S assay system, whereas those of PT-based protein S activity and free protein S antigen were assessed using clot-based method and latex agglutination method, respectively. PT, prothrombin time.](blcof-30-393-g001){#F1}

The diagnostic accuracy of differentiating heterozygous individuals for protein S Tokushima variant from wild-type individuals was then compared with the value closest to the lower limit of the reference interval (mean-2× SD) of each parameter being selected as a cut-off value (Table [2](#T2){ref-type="table"}). The cut-off value for total protein S activity, 74.5 IU/dl, was higher than that for PT-based protein S activity, 56.5 U/dl; however, the discriminatory power of total protein S activity was stronger than that of PT-based protein S activity, particularly for sensitivity, 77.8 vs. 22.2%. The AUC value of the total protein S activity/total protein S antigen ratio (protein S-specific activity) was the highest among the six parameters at 1.000, and sensitivity and specificity were 100.0 and 96.9%, respectively. Furthermore, by setting the cut-off value of the total protein S activity/total protein S antigen ratio to 0.78, mean-3× SD, sensitivity and specificity both further improved to 100%. As the reference interval of the PT-based protein S activity/free protein S antigen ratio was not provided, its cut-off value was temporarily set as the same value as that for the total protein S activity/total protein S antigen ratio; however, its diagnostic accuracy was inferior to that of the total protein S activity/total protein S antigen ratio, with an AUC value, sensitivity, and specificity of 0.972, 100%, and 87.7%, respectively.

###### 

Diagnostic accuracy of parameters of plasma protein S phenotypic analyses for heterozygous individuals for the protein S Tokushima (p.Lys196Glu) variant

                                                             Cut-off      Sensitivity (%)   Specificity (%)   AUC (95% CI)           *P* value[^a^](#TF2-1){ref-type="table-fn"}
  ---------------------------------------------------------- ------------ ----------------- ----------------- ---------------------- ---------------------------------------------
  Total protein S activity                                   74.5 IU/dl   77.8              94.6              0.941 (0.871--1.000)   \<0.001
  Total protein S antigen                                    76.0 IU/dl   0.0               98.5              0.402 (0.236--0.568)   0.327
  Total protein S activity/total protein S antigen ratio     0.855        100.0             96.9              1.000 (1.000--1.000)   \<0.001
  PT-based protein S activity                                56.5 U/dl    22.2              97.7              0.924 (0.858--0.989)   \<0.001
  Free protein S antigen                                     59.5 U/dl    0.0               98.5              0.456 (0.282--0.630)   0.659
  PT-based protein S activity/free protein S antigen ratio   0.855        100.0             87.7              0.972 (0.946--0.999)   \<0.001

AUC, area under the curve; CI, confidence interval; PT, prothrombin time.

^a^Logistic regression analysis.

Discussion
==========

Hereditary dysfunctions in the protein C anticoagulant system represent the main thrombophilia in Asia \[[@R3],[@R22]\]: the *PROS1* variant, protein S Tokushima (p.Lys196Glu), and two *PROC* variants, protein C p.Arg189Trp and protein C p.Lys193del, are both genetic risk factors for VTE and prevalent among Japanese \[[@R4]--[@R6]\] and Chinese populations \[[@R7]--[@R9]\], respectively. The plasma phenotypes of these three gene variants are a qualitative (type II) deficiency, and therefore their diagnosis by plasma analyses is difficult \[[@R12]--[@R15]\]. Furthermore, plasma protein S levels show marked differences related to sex and age \[[@R17],[@R18]\], being the lowest in premenopausal young women, and thus we conducted genotype and plasma phenotype analyses on young Japanese women of approximately 20 years old.

In genotype analyses of participants (*n* = 231), we found protein S Tokushima and protein C p.Lys193del variants to be prevalent with allele frequencies of 1.08 and 0.86%, respectively; however, no carrier of the protein C p.Arg189Trp variant was identified. Therefore, one out of every 25 target individuals were found to have a genetic risk factor for VTE. The allele frequency of protein S Tokushima in the present study was slightly higher than that reported previously for the Japanese general population at 0.6--0.9% \[[@R4]--[@R6]\]. Matsumoto et al. \[[@R23]\] recently showed that the allele frequency of the protein C p.Lys193del variant was 0.24% among 637 healthy Japanese individuals. A predisposition for the protein C p.Lys193del variant among Japanese DVT patients has been reported: two heterozygotes in 85 patients \[[@R4]\] and four heterozygotes in 173 patients \[[@R24]\], indicating an allele frequency in DVT patients of approximately 1.2%. This value was significantly lower than that in Chinese VTE patients (3.4%) \[[@R9]\]; however, the protein C p.Lys193del variant may also be a common genetic risk factor for DVT among the Japanese population. Recently, the protein C p.Lys193del variant was reported to be prevalent among Japanese neonatal thrombosis patients with a protein C deficiency \[[@R25],[@R26]\].

We then analyzed the plasma phenotypes of the heterozygous carriers of the protein S Tokushima or protein C p.Lys193del variant. The plasma phenotype of type II deficiency of the heterozygotes for protein S Tokushima was clearly demonstrated by moderately decreased levels of total protein S activity, measured by a chromogenic-based assay, with normal total protein S antigen levels relative to those of wild-type individuals, resulting in a significantly decreased total protein S activity/total protein S antigen ratio (protein S-specific activity). A previous study demonstrated that the protein C activities of the protein C p.Lys193del variant measured by a clot-based assay were significantly decreased, whereas their protein C activities measured by a chromogenic assay were not different from those of normal individuals \[[@R9]\]. In the present study, however, the clot-based protein C activities of heterozygotes for the protein C p.Lys193del variant were all within the reference interval, and their protein C antigen levels were significantly higher than those of wild-type individuals, resulting in a moderately decreased protein C activity/protein C antigen ratio. In a previous study on healthy Japanese individuals, the clot-based protein C activities of two out of three heterozygotes for protein C p.Lys193del variants were also within the reference interval \[[@R23]\]. Thus, it appears that the heterozygous carriers of protein C p.Lys193del variant may not be identified either by clot-based or chromogenic protein C activity assay. In an in-vitro expression experiment, the transcription level of protein C p.Lys193del mutant was found to be approximately 1.3-fold higher than that of wild-type protein C, whereas the concentration of mutant protein C in culture media, having moderately decreased anticoagulant activity, was similar to that of the wild type \[[@R9]\]. Another in-vitro expression experiment reported a relatively low anticoagulant activity of the protein C p.Lys193del mutant only in the presence of protein S \[[@R27]\]. Further experiments need to be performed in order to clarify whether this deletion of a lysine in the sequence Lys-Lys-Arg-Ser-His-Leu upstream of the C terminus of the light chain of the protein C molecule affects secretion of protein C.

The APC cofactor activity of protein S has commonly been measured using clot-based assays, mainly PT-based and APTT-based assays \[[@R12],[@R13]\]. We compared the diagnostic accuracy of a PT-based assay for protein S Tokushima (p.Lys196Glu) heterozygous carriers to that of the chromogenic-based assay of the total protein S assay system. The PT-based protein S activity levels of wild-type individuals were distributed over a wide range and overlapped completely with the range of heterozygous individuals, as observed in an APTT-based protein S activity assay \[[@R21]\], and thus, sensitivity was found to be 22.2% when the cut-off value was set to the lower limit of the reference interval. Three wild-type individuals had significantly decreased PT-based protein S activities; a propensity for spuriously low clot-based protein S activities in normal individuals has also been reported \[[@R28]\]. In contrast, the total protein S activity levels of wild-type individuals were distributed within a narrower range, but partially overlapped with those of heterozygous individuals, resulting in a higher discriminatory power, a sensitivity of 77.8%, even though the cut-off value was higher than that of PT-based protein S activity. The distribution of the PT-based protein S activity/free protein S antigen ratios of wild-type individuals and that of the heterozygotes completely overlapped, whereas that of the total protein S activity/total protein S antigen ratios of wild-type individuals did not overlap with that of heterozygous individuals. The sensitivity and specificity of the total protein S activity/total protein S antigen ratio were 100 and 96.9%, respectively, when the cut-off value was set to the lower limit of the reference interval, but improved to 100% each when the cut-off value was 0.78, mean-3 × SD. These results clearly demonstrate that total protein S activity is superior as a screening examination and the total protein S activity--total protein S antigen ratio as a diagnostic examination of a type II protein S deficiency with moderately decreased protein S activity, such as protein S Tokushima.

In plasma, protein S circulates in its free form and in the protein S-C4BP complex, and the latter loses its APC cofactor activity \[[@R10]\]. The dissociation of the protein S-C4BP complex is extremely slow (*K*~d~ = 0.1 nmol/l) in the presence of a physiological concentration of Ca^2+^; however, affinity was shown to decrease (*K*~d~ = 6.5 nmol/l) in the absence of Ca^2+^, such as in citrated plasma \[[@R11]\]. The dissociation of the protein S-C4BP complex increases in time-dependent, temperature-dependent, and dilution-dependent manners, and affects the measurement of free protein S antigen \[[@R29],[@R30]\] and possibly protein S activity levels. Furthermore, the protein S-C4BP complex has been reported to retain cofactor activity for APC-catalyzed proteolysis at Arg^306^ in factor Va, but gain inhibitory activity for proteolysis at Arg^506^, which might be responsible for the inhibitory activity of C4BP added to plasma in clot-based assays \[[@R31]\]. These characteristics of the protein S-C4BP complex may contribute to the analytical variables of clot-based assays. In the total protein S assay system, the undesired effects of the dissociation of the protein S-C4BP complex were avoided: by diluting samples with a high dilution ratio and adding liposomes with high affinity for protein S in the total protein S activity assay; by adding an excess amount of purified human C4BP to make free protein S combine with protein S in the total protein S antigen assay \[[@R16]\]. Total protein S activity is then measured by a chromogenic-based method in which the degradation of factor Va in the prothrombinase complex is evaluated by the thrombin production rate; and total PA antigen levels by a latex-agglutination method. Both assays may be performed using an automated analyzer, and, thus, rapid performance and excellent reproducibility have been achieved. Clot-based protein S assays were previously reported to overestimate protein S activity in patients being treated with direct oral anticoagulants (DOACs) \[[@R32],[@R33]\]. We recently demonstrated that the total protein S activity assay is not interfered with DOACs, including dabigatran, rivaroxaban, apixaban, and edoxaban \[[@R34]\].

This study has some limitations. The number of participants, particularly of the carriers of variant alleles, was small, and, thus, large-scale population studies are needed to confirm the findings on genotypes and plasma phenotype analyses. Furthermore, as we only analyzed healthy individuals, case\--control studies need to be performed in order to confirm the accuracy of the total protein S assay system for diagnosing carriers of protein S Tokushima variants with thrombosis. In addition, we did not analyze the whole sequences of *PROS1* and *PROC*, and thus the effects of variants other than those examined have yet to be assessed. Moreover, we have not yet investigated the effects of the factor V Leiden protein in the total protein S activity assay because of its absence among the Japanese population \[[@R3]\].

In conclusion, the present study demonstrated that the protein S Tokushima (p.Lys196Glu) and protein C p.Lys193del variants are prevalent in young Japanese women, whereas the protein C p.Arg189Trp variant is not. The plasma phenotype of a type II deficiency in protein S Tokushima heterozygotes was clearly demonstrated by decreased total protein S activity with a normal total protein S antigen level; however, the clot-based protein C activities of protein C p.Lys193del heterozygotes were all within the reference interval, whereas their protein C antigen levels were elevated. Diagnostic accuracy assessed from ROC curves indicated that a plasma analysis using the total protein S assay system, measuring total protein S activity and total protein S antigen levels, is superior to that evaluating clot-based protein S activity and free protein S antigen levels for diagnosing protein S Tokushima carriers.
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